Nkgen Biotech, Inc.
Clinical trials sponsored by Nkgen Biotech, Inc., explained in plain language.
-
New Alzheimer's treatment enters human testing
Disease control Recruiting nowThis early-stage study aims to test the safety and side effects of an experimental treatment called SNK01 for people with moderate Alzheimer's disease. Researchers will give SNK01 as an intravenous infusion every three weeks for up to one year to 36 participants. The study will a…
Phase: PHASE1, PHASE2 • Sponsor: NKGen Biotech, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Alzheimer's patients continue experimental therapy in Long-Term safety study
Disease control Recruiting nowThis study continues testing an experimental treatment called SNK01 in people with Alzheimer's disease who completed an earlier trial. It aims to check the long-term safety and side effects of receiving SNK01 infusions every three weeks. Researchers will also look for any changes…
Phase: PHASE2 • Sponsor: NKGen Biotech, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC